Federal Policy Update - July 2022

Read the July 2022 federal policy update to learn about the results of the June 28th House Committee on Energy and Commerce Subcommittee on Oversight and Investigation hearing on “Protecting America's Seniors: Oversight of Private Sector Medicare Advantage Plans."

2022 Special Election Results

Congratulations to the newly elected Officers and Board Members! We are confident that AACE will be well served by their contributions.

Working to Improve Adult Immunizations in Diabetes Patients Through a Multi-year National Quality Improvement Collaborative

AACE has been named one of seven subspecialty societies to participate in a Centers for Disease Control and Prevention (CDC)-funded grant project led and coordinated through the Council for Medical Specialty Societies to help increase COVID-19, influenza, and routine vaccinations in high-risk adults with chronic medical conditions.

Notice of AACE Special Election for President Elect, Treasurer and Secretary

In compliance with Chapter 6 of the AACE Bylaws*, this Memorandum serves to officially notify you in writing that the Board of Directors, upon an affirmative 2/3 vote, approved the AACE Nominating Committee slate of candidates for the special election for AACE President Elect, Treasurer and Secretary for a one-year term to begin January 1, 2023, and end on December 31, 2023.

FY 2023 Federal Government Omnibus Appropriations Bill

On December 29, 2022, the President signed the Consolidated Appropriations Act, 2023 [P.L. 117-328]. Read our federal policy blog to learn about the key items in the new law.

Federal Policy Update - March 2023

On February 16, 2023, President Biden signed a notice announcing the final extension of the Public Health Emergency (PHE) with a termination date of May 11, 2023. Read our federal policy blog update to learn about the termination of the Public Health Emergency (PHE) policy and its implications, as well as updates on the FTC allegations against GoodRx, economic data, and Medicare Advantage enrollment.

Federal Policy Update - May 2022

In this update on federal policy in health care, read about the rules and other items that are under OIRA review, the recent pharmacy benefit managers Congressional hearing, and more.

Federal Policy Update - June 2022

Read the June 2022 federal policy update to learn about interchangeable biological products from the FDA, the latest enrollment figures for Medicare, Medicaid, and CHIP released by the CMS, house republican health policy proposals, 2022 social security and Medicare trustees’ reports, and more.

Federal Policy Update - February 2023

On February 1, 2023, the U.S. House of Representatives passed H. J. Res. 7, by a vote of 229-197 (7 not voting). This bill would terminate the COVID-19 National Emergency and the Public Health Emergency (PHE) immediately. Read our federal policy blog to learn about the significant changes.

Help Us Develop A Consensus Statement On Acromegaly — Deadline July 26

We're seeking chairs, authors, and a methodology fellow to develop a consensus statement on acromegaly. Learn how to apply today!

Coalition of Bone Health Experts Issues Joint Guidance on Osteoporosis Management in the Covid-19 Era

Organizations responding to "paucity of data” to provide clear guidance for healthcare professionals treating millions of osteoporosis patients.

Announcement: New  Editors-in-Chief and publishing changes  for  Endocrine Practice  and  AACE  Clinical Case Reports

We are pleased to announce that new Editors-in-Chief have been selected for both Endocrine Practice and AACE Clinical Case Reports. In addition to this new editorial leadership, we are also announcing a partnership with Elsevier to publish both journals beginning January 1, 2021.

Joint Guidance on COVID-19 Vaccination and Osteoporosis Management from AACE, ASBMR, Endocrine Society, ECTS, IOF, and NOF

Joint Guidance on COVID-19 Vaccination and Osteoporosis Management from the American Society for Bone and Mineral Research (ASBMR), American Association of Clinical Endocrinology (AACE), Endocrine Society, European Calcified Tissue Society (ECTS), the International Osteoporosis Foundation (IOF), and the National Osteoporosis Foundation (NOF)  

Federal Policy Update - July 20, 2022

Read the July 2022 federal policy update to learn about the Centers for Medicare and Medicaid Services (CMS) newly released proposed 2023 Medicare physician fee schedule rule

Members only: Annual Business Meeting Recap

An update on outcomes of the virtual Annual Business Meeting that occurred on September 11, 2020.

2021 FACE Application Period is Open Through November 2

The FACE application period is open until November 2, 2020. Applications will only be accepted online, and eligible candidates must meet the criteria set forth by the FACE Application Committee.

4 ways you can learn about the new 2020 Postmenopausal Osteoporosis Guidelines

Here is a round-up of four different online, on-demand courses you can take that will walk you through the guidelines and help you apply them to your practice.

Federal Policy Update

On May 25, the Senate confirmed Chiquita Brooks-LaSure to be the Centers for Medicare and Medicaid Services Administrator by a vote of 55-44. She was sworn in two days later. In her first interview, Brooks-LaSure stated that her top priorities will be to expand health insurance coverage and address health disparities.

Presenting PrescriptionHelp.aace.com – A directory of endocrine prescription affordability programs

Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.

In Memoriam: Alan J. Garber, MD, PhD, MACE

It is with great sadness that I share the news of Dr. Alan Garber’s passing yesterday on April 9, 2020. Dr. Garber was a Charter Member of AACE, as well as a Past President of both AACE and ACE.

AACE 2020 Election Results

We are pleased to report to you the results of the AACE 2020 elections. Dr. Daniel L. Hurley, Chair of the Nominating Committee, thanks the members of the Nominating Committee for their time and effort evaluating a number of excellent candidates for Officer positions and the Board of Directors and for developing a strong slate of candidates for the 2020 election.

FDA approves additional doses of Trulicity® (dulaglutide) for the treatment of type 2 diabetes

The U.S. Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg in people with type 2 diabetes.

AACE Position Statement: Coronavirus (COVID-19) and People with Diabetes

As the coronavirus (COVID-19) continues to spread in the United States, it is important for every

Medicare to Temporarily Cover All Clinicians to Provide Telehealth Services

In an effort to limit the spread of the coronavirus, the Trump Administration announced today that it is expanding Medicare telehealth coverage so that beneficiaries can receive healthcare services without having to travel to their physician's office.

Lilly introduces Insulin Value Program, featuring $35 copay card for patients with diabetes

Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.

AACE Position Statement: Coronavirus (COVID-19) and People with Diabetes (Updated March 18, 2020)

AACE releases update on COVID-19 and the risks and recommended preparations for patients with diabetes.

FDA issues warning: cyber threats lead to recall of certain insulin pumps

The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.

FDA Releases New Nutrition Facts Label for the First Time in 20 Years

The U.S. Food and Drug Administration has updated the Nutrition Facts label.

The Lowdown on Low Blood Sugar Campaign

AACE is excited to announce 'The Lowdown on Low Blood Sugar' campaign.

Insulin Manufacturing and Distribution Capabilities Currently Stable During COVID-19 Pandemic

At this time, the leading pharmaceutical manufacturers are reporting that COVID-19 is NOT having an impact on their manufacturing and distribution capabilities for insulin and other related supplies.

AACE Position Statement: Coronavirus (COVID-19) and People with Adrenal Insufficiency and Cushing’s Syndrome

With the novel COVID-19 virus continuing to spread, it is crucial to adhere to the advice from experts and the Centers for Disease Control and Prevention (CDC) to help reduce risk of infection for individuals and the population at large. This is particularly important for people with adrenal insufficiency and people with uncontrolled Cushing’s Syndrome.

No Surprises Billing Proposed Regulations

On July 1, 2021, the “No Surprises Act” Interim Final Rule, Part I, was issued. Learn how this announcement is the first in a series of regulations aimed at shielding patients from increased financial hardships stemming from surprise medical bills.

COVID-19 News: Industry Manufacturer Announces Insulin Savings Program

A new $35 co-pay is available through the Lilly Insulin Value Program in response to the COVID-19 crisis in the U.S.

Former AADE rebrands as Association of Diabetes Care & Education Specialists

The former American Association of Diabetes Educators is now the Association of Diabetes Care & Education Specialists (ADCES). The rebranding reflects the association’s shift from referencing the specialty title as “diabetes educator” to the more comprehensive “diabetes care and education specialist.”

New Updates to the AACE Diabetes Algorithm

The AACE diabetes algorithm is a comprehensive management algorithm that covers lifestyle, obesity, prediabetes, lipids, hypertension and glucose management strategies.

AACE Position Statement: Coronavirus (COVID-19) and People with Thyroid Disease

There is currently no reason to believe that most people with thyroid disease are at increased risk to contract this novel coronavirus or to experience complications. Nevertheless, if thyroid medications are not taken as prescribed, uncontrolled thyroid disease may increase a person’s risk for viral infection and complications.

RECALL: Medtronic MiniMed Insulin Pumps Recalled for Incorrect Insulin Dosing

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Click to read which models are affected.

AACE Position Statement: Coronavirus (COVID-19) and People with Cardiometabolic Disease

Initial research suggests that people with cardiometabolic disease are at increased risk of experiencing complications from infection with COVID-19 and may be more susceptible to contracting the virus.

New Direct-to-Patient Pharmacy Program Helps Abbvie Provide Thyroid Patients Better Access to Synthroid

AbbVie has launched a new SYNTHROID DELIVERS PROGRAM, a direct-to-patient pharmacy program that offers patients a cash-pay option to receive Synthroid consistently and conveniently.

Explore the Improved AACE Learning Center (Updated with Instructions)

AACE is excited to share all the benefits of this improved system with you.

Takeda Announces Recall of NATPARA (parathyroid hormone) for Injection

Pharmaceutical company Takeda has announced the recall of the its parathyroid hormone for injection, NATPRA.

Federal Policy Update - December 2021 - January 2022

On December 3, 2021, President Biden signed the "Further Extending Government Funding Act". Public Law 117-70 funds the Federal government through February 18, 2022. It is likely Congress will again consolidate all the bills into one large appropriations bill. The big question is whether Congress can achieve an agreement on full year appropriations or simply pass another continuing resolution.

President/CEO Update to AACE Members – April 2020

We continue to think of you during this unprecedented season. While over the last several weeks you have received many helpful pieces of guidance, research, and news updates - today we simply wish to remind you that our priority remains to be you: our members. You are the heart of AACE, and you are our foremost thought that guides anything and everything we do.

President Update to AACE Community – January 2022

AACE leadership spent the last year developing our 2022-2025 strategic plan, and one of our three focus areas is patient and public awareness. AACE President Dr. Felice Caldarella shares how we are further expanding and updating our patient and public resources by featuring “AACE Patient Journeys”, along with other new developments including our involvement in helping to obtain Congressional approval for the National Clinical Care Commission (NCCC) recommendations on diabetes care, and more.

Deadline Extended Call for Papers: 2023 Endocrine Practice Journal Symposium

Apply now: Editor-in-Chief Positions for AACE Scientific Journals

AACE invites nominations and applications for two, separate positions:

Video: AACE President Annual Address - May 2020

Dr. Sandra Weber, AACE President 2019-2020, and Dr. Howard Lando, AACE President 2020-2021, deliver addresses to the American Association of Clinical Endocrinologists (AACE) community. Introduction by Paul Markowski, AACE CEO.

Announcing our 2021 Awards, MACE and FACE recipients

Congratulations to our 2021 Awards, MACE and FACE recipients. All recipients will be honored during our 2021 Annual Meeting.

Improving the Lives of Veterans With Diabetes

We’ve partnered with Beyond Type 1, a nonprofit organization aiming to unite the global diabetes community and provide solutions to improve lives, to develop Armed For Diabetes,* a campaign to educate veterans on how they can gain access to the latest diabetes management tools.

Non-Insulin Injectable Therapies for Diabetes Management

An estimated 30.3 million Americans have type 2 diabetes (T2D), a complex, progressive disease th

Official Statement on Adrenal Incidentalomas Guidelines

In the systematic review and meta-analysis of more than 4,000

AACE 2020 Elections: Preliminary Notice of Candidates

In compliance with the AACE Bylaws, the AACE Nominating Committee is pleased to notify the membership of the selection of the following preliminary slate of candidates for election to Officer positions for a one-year (1) term.

Calendar Year (CY) 2022 Medicare Physician Fee Schedule Proposed Rule

On July 13, 2021, the Centers for Medicare and Medicaid Services (CMS) posted the proposed rule for the 2022 Physician Fee Schedule (PFS) and other Medicare Part B issues. Learn how the results can bring better accessibility, quality, affordability, empowerment, and innovation.

Warning: Recent Uptick in F.A.C.E. Scams

We have been notified of several fellowship and medical board scams that are targeting physicians by offering a medical certification and/or endocrinology fellowship designation (FACE) from a medical association for a fee.

How AACE is Leading the Way for Clinical Endocrinology

An update for current AACE members. On October 20, 2020 - we launched a transformed AACE brand and community. While there are a number of changes that were revealed on October 20, here is what you need to know about our direction.

FDA Requests Withdrawal of Belviq XR (lorcaserin) from the Market

Due to signals in safety clinical trials showing possible increased risk of cancer, The U.S. Food and Drug Administration (FDA) requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market.

AACE Joins Forces with Major Scientific Organizations in a Pledge to End Obesity Stigma

Coinciding with World Obesity Day, AACE has joined over 100 medical and scientific organizations across the world in pledging our support for a consensus statement that recognizes unscientific public narratives of obesity as a major cause of weight stigma and calls for strong policies and legislation to prevent weight-based discrimination.

Thyroid Eye Disease Resource Center

Read more about thyroid eye disease, including recent research and case studies from Endocrine Practice and AACE Clinical Case Reports.

AACE is Closely Monitoring Global Novel Coronavirus COVID-19 Threat

AACE is closely monitoring the information being shared about the virus and will take the precautions needed to promote the health and safety of our staff and members attending the EMBRAACE annual meeting.

U.S. President Takes Action to Lower Drug Prices for Americans

President Trump signed four executive orders aimed at lowering the prices Americans pay for prescription drugs, including insulin.

2022 Meetings Update from CEO Paul Markowski

After over a year of producing virtual events during an uncertain time, we are planning for a potential return to in-person events that brings both excitement and new opportunities. As a valued member of our AACE Community, I would like to be transparent with you and share how we are planning a return to in-person conferences in 2022.

‘Who, What, Where & Why’ with AACE International Clinician Award Recipient

In a recent interview with the AACE2019News.com, Yulino Castillo Núñez, MD, recipient of the 2019 AACE International Clinician Award, discussed some of the greatest influences on his career in endocrinology.

Anxiety More Common Than Depression in Euthyroid Patients With Thyroid Disease

Significantly more euthyroid patients

The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment

Chait, A. and Eckel, R. The Chylomicronemia Syndrome Is Most Often Multifactorial.

Members only: Information on the Annual Business Meeting

The Annual Business Meeting of the AACE membership will be held via a ZOOM Virtual Conference Call on Friday, September 11, 2020, from 4:00 pm – 5:00 pm EST. Registration is required.

Federal Policy Update - Nov. 2021

On November 19th, the U.S. House of Representatives passed H.R. 5376, the “Build Back Better Act”. Learn about the new federal policy updates and how it will support the major health care provisions in H.R. 5376.

In Memoriam: Lewis E. Braverman, MD, MACE

Lewis E. Braverman, MD, MACE, 89, passed away peacefully on Monday, June 10, 2019. He leaves his wife Mimi Braverman; his sons, William Braverman and Daniel Braverman; and his five grandchildren.

Levoketoconazole Improves Biochemical and Clinical Parameters in Patients With Cushing Syndrome

Biochemical markers and clinical signs and symptoms of endoge

Triglyceride and Triglyceride/ HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease

Prasad, M. et al.

Video: Important AACE Member Update

Drs. Leslie Eldeiry, Scott Isaacs, and Matthew Levine provide an important AACE member update on behalf of the Board of Directors on two upcoming changes regarding our brand and community. These will be further discussed at the Annual Business Meeting on September 11, 2020.

Introducing AACE Communities

Coming soon: a new way to connect with your peers on a micro level

Emerging data support anabolic-first regimens for severe osteoporosis

AACE Member Fel

Cortisol Pumps May Be Viable Option to Reduce Adrenal Crisis in Severe Adrenal Insufficiency

The use of an insulin pump to deliver continuous pulsatile co

The Outlook For Telehealth Post COVID-19 Pandemic

The Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 [Public Law 116-123] authorized the Secretary of Health and Human Services (HHS) to waive statutory requirements with respect to telehealth services under Medicare for the duration of the COVID-19 Public Health Emergency.

Type 2 diabetes remission: Reducing excess fat in the liver might be the key

AACE Member Roy Taylor, MD

Abaloparatide Followed by Alendronate Shows Promising Results for Women With Osteoporosis, T2D

Abaloparatide

FDA OKs First-Ever Nasal Glucagon for Severe Hypos in Diabetes

Medscape reports the nasal powder, used in the treatment of severe hypoglycemia for patients aged 4 years or older, is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.

Announcing 2020 AACE/ACE Awards, MACE and FACE Recipients

Though we sadly cannot celebrate in person at our annual congress, we are happy to congratulate o

In Memoriam: Daniel S. Duick, MD, FACP, MACE, ECNU

Former AACE President, Daniel S. Duick, MD, FACP, MACE, ECNU, passed peacefully, surrounded by family on January 5, 2022. He was an inspiration to the endocrine community as an endocrinology, diabetes and metabolism specialist with more than 55 years of experience in the medical field.

Members of Congress Seek to Reform MACRA

A bipartisan group of eight House lawmakers, spearheaded by Reps.

In Hemodialysis, Something Better Than BMD to Predict Fracture Risk

Among patients on hemodialysis, trabecular bone score was helpful i

Linagliptin Does Not Increase Adverse Renal Events in Patients With T2D, Kidney Disease

Treatment with linagliptin

A Message to AACE Members Regarding CMS Proposed Rules

Medicare imposed substantial cuts in reimbursements for the new and revised fine needle aspiration codes for 2019. AACE, together with the Endocrine Society and American Thyroid Association, advocated for you with letters to Centers for Medicare and Medicaid Services (CMS) and Congress opposing these cuts. We secured a win with the release of the proposed physician pay rule issued July 29. 

How AACE is Leading the Way for Clinical Endocrinology

Join us on October 20, 2020 as we launch a new AACE.

Severe Shortage of Treatments for Diabetes in Tigray, Ethiopia

There is a severe shortage of diabetes medicines in the Tigray region of Ethiopia, jeopardizing thousands of persons with diabetes. We urge both government organizations and non-government organizations, including manufacturers to strive to improve access to life-saving treatments for diabetes in the Tigray region. Read our full statement to learn more.

Rapid Recap for Advanced Diabetes Technology – Conversations and Collaborations

Benefits of Continuous Glucose Monitoring 

Improvements in Excess Cortisol Activity With Relacorilant

The investigational agent relacorilant significantly improved exces

Type 2 Diabetes Associated With Short-Term Risk for Fracture

Type 2 diabetes

CDC Prediabetes Test Goal to Increase Public Awareness

The CDC recently launched in collaboration with Google Health, a prediabetes quiz that will pop up when end users search for certain medical information using their Google browser to bring more public awareness about prediabetes.

Federal Policy Update - February 2022

The current continuing resolution funds the Federal government until February 18, 2022. The House and Senate Appropriations Committees Chairs and Ranking Members continue their negotiations. Learn about the latest updates on the Congressional Budget Office Report, No Surprises Billing Information, President’s Stimulus Bill, and much more.

AACE Statement on Clinician - Patient Relationship

Statement: 

Novel Agent Reduces Bulging Eyes in Thyroid Eye Disease

The investigational agent teprotumumab was effective for reducing p

In-hospital diabetic ketoacidosis mortality risk higher on the weekend

Findings presented at the AACE 28th Annual Scientific & Clinical Congress showed that seeking

AACE Members Aided in Government's New Obesity Study

The Government Accountability Office (GAO) has released a new study on prescription drug use to treat obesity.

The Health Care Workforce Shortage Issue In Congress

The COVID-19 pandemic revealed to Federal public policymakers and the general public the need for more health care providers. More importantly, there was a greater realization of a shortage in underserved areas, particularly in certain urban, rural, and Native American settings. Learn how congress is solving the crisis in the health care workforce.

AACE Position Statement: Transgender and Gender Diverse Patients and the Endocrine Community

We at AACE strongly believe that decisions impacting health care of endocrine patients are best left to the health professional, the patient, and the patient’s families for all medical care. Read our position statement on transgender and gender diverse patients to learn more.

Call for Nominations for Fall 2023 Special Election

Dear Colleague,

Molecular Test Promising for Mutations in Thyroid Nodules

The ThyroSeq v3 Genomic Classifier was able to effectively classify

A Ripple of Change: Social Media, Gender Diversity, and Updated Lecture Formats at AACE

This year, at the 28th Annual Scientific & Clinical Congress, AACE made changes to the tradit

Industry News: Resources to Stay Connected

Disclaimer: This message contains paid content from our sponsors. 

President Biden's FY 2022 Budget and Revenue Proposals

On May 28, President Biden released his FY 2022 budget and revenue proposals. Learn about the breakdown of the health care budget proposals.

Ongoing Severe Shortage of Treatments for Diabetes in Tigray, Ethiopia

In February, 2022, AACE supported an urgent call for action to address the serious health delivery issues that patients with diabetes were facing in the Tigray Region of Ethiopia as a result of the ongoing conflict between the Federal Government and the Tigray Regional Government. We are deeply concerned about the ongoing barriers to delivering life-saving supplies and medications to innocent people of Tigray, suffering with diabetes. Read our full statement to learn more.

Serum Steroid Profiles May Help Differentiate Adrenal Tumors

Distinctive serum steroid profiles might emerge in patients with ad

Beyond calcium, vitamin D, supplements may do more harm than good for bones

When it comes to optimal bone health and fracture prevention, there is scant evidence for recomme

COVID-19 Resources: Telehealth, Updates and More

AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.

Telemedicine checklist: 3 steps to prepare for your virtual visit

In the era of COVID-19, many in-office visits have been able to convert to virtual appointments. Many ask, how is a telemedicine visit different, and how can I get the most from it?

Nominate Your Colleagues for the 2021 AACE Awards

The nomination submission period closes November 20, 2020 at 11:59 pm EST. The 2021 AACE Awards will be presented during AACE's 30th Annual Meeting in May 2021.

New Edition of AACE's Self-Assessment Program (ASAP) Now Available

Building off of last year’s successful new format, AACE is pleased to announce the newest edition of the AACE Self-Assessment Program (ASAP)!

Top takeaways from AACE 2019

Endocrine Today has

How to Capture Virtual Check-Ins Appropriately

As of January 1, 2019, Medicare will pay separately for a newly defined type of physicians' servi

Community Perspective: FDA OKs Injectable Semaglutide for Chronic Weight Management

Monica Agarwal MD, MEHP, FACE, provides her perspectives on the recent FDA approval of Semaglutide as an addition to the therapeutic armamentarium of weight management options for people living with obesity. Learn her key takeaways and how the new injectable semaglutide can support adults living with obesity.

AACE Community Perks

Check out these great resources at AACE!

Federal Policy Update - November 2022

The Centers for Medicare and Medicaid Services (CMS) released the CY 2023 physician fee schedule final rule, hospital outpatient prospective payment system, and ambulatory surgical center payment rule. Read our November 2022 federal policy blog to learn about the updates.

Cardiovascular Effects of Canagliflozin Vary According to Concomitant Metformin Use

The cardiovascular and renal effects of treatment with canagliflozi

New campaign encourages people to take action to access lower costs for Lilly insulin

Lilly has launched “Insulin Affordability: Learn. Act.

Federal Policy Update - July 2021

In June the U.S. Supreme Court came to the end of its term. Meanwhile, Congress has begun the budget/appropriations process. Learn about the latest federal policy updates and how it can impact the future of health care.

Social Determinants of Health Affect the Care Experience of Overweight Patients

Lower income and education levels may negatively affect the e

COVID-19 Public Health Emergency Declaration Extended Another 90 Days

The COVID-19 public health emergency declaration has officially been extended for another 90 days

Guide to Browsing Our Educational Opportunities

Welcome to the new pro.aace.com!

Announcing our 2022 Awards, MACE and FACE recipients

Congratulations to our 2022 Awards, MACE and FACE recipients. All recipients were honored during our 2022 Annual Meeting.

Newly Identified Ultrasound Characteristic May Predict Thyroid Nodule Malignancy Risk

For indeterminate thyroid nodules

Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study

Schleyer T, Hui S, Wang J, et al.

AACE Policy Statement: Access to Diabetes Medication and Technology

A new policy statement from AACE including background and recommendations for access to diabetes medication and technology

Open Now: 2021 Call for Nominations for Election to the AACE Board of Directors

Nominate your colleagues as candidates for election to the AACE Board of Directors to fill terms

Teprotumumab Effectively Reduces Proptosis in Active Thyroid Eye Disease

Teprotumumab effectively reduces proptosis in patients with a

Association between statin treatment and new-onset diabetes mellitus: a population based case-control study

Kim DW, et al.

World Diabetes Day: AACE Supports Educating the Endocrine Care Team and Beyond

This World Diabetes Day, we at the American Association of Clinical Endocrinology (AACE) extend o

Help Us Update Our Dyslipidemia Guideline — Deadline July 5

We're seeking authors and a methodology fellow to update the 2017 AACE Clinical Practice Guideline for the Management of Dyslipidemia and Prevention of Cardiovascular Disease. Learn how to apply today!

Hypothyroidism a Risk Factor for Mortality in Congestive Heart Failure

Hypothyroidism

Statins for Primary Prevention in Those Aged 70 Years and Older: A Critical Review of Recent Cholesterol Guidelines

Hawley CE, et al.

AACE Elections: Here's Our Preliminary Candidates

In compliance with the AACE Bylaws, we’re sharing with you the following preliminary slate of candidates for election to officer positions for a one-year (1) term. For the Board of Directors, there are five (5) open positions for election to a three-year (3) term (2021-2024), one (1) open position for a two-year (2) term (2021-2023), and one (1) open position for a one-year (1) term (2021-2022).  

AACE Communities coming to Latin America and Asia-Pacific regions

With our recent announcement about the new AACE Communities initiative that will offer regional events at a global scale, we are happy to share that MCI is teaming up with AACE as a regional office to bring educational opportunities and more to areas within Latin America and Asia-Pacific.

Five Questions with AACE 2019 Keynote Speaker Kevin Pho, MD

Kevin Pho, MD, is a board-certified internal medicine physician and founder of

Novel Cardiometabolic Staging Tool Predicts T2D Risk in Diverse Population

A weighted cardiometabolic disease

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

Arnett DK, Blumenthal RS, Albert MA et al.

AACE Position Statement: Coronavirus (COVID-19) Vaccine and the Endocrine Community

The COVID-19 pandemic entered a new promising phase when the first vaccines for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection became available in late 2020. We at AACE have recommendations for both endocrine patients and care providers.

Medicare Payment Rules

On November 2, 2021, the U. S. Department of Health and Human Services Centers for Medicare and Medicaid Services released several final Calendar Year 2022 payment rules. Learn how these rules cover physician fee schedule, hospital outpatient and ambulatory surgical centers, and more.

AACE Supports CMSS Statement on Recent Supreme Court Decision

The Council of Medical Specialty Societies (CMSS), a coalition of 48 specialty societies (including AACE), strongly denounces any interference into the practice of medicine that undermines the integrity of the patient-physician relationship.

CMS Releases Final 2020 Physician Fee Schedule - 16% Increase for Endocrinology

The Physician Fee Schedule for CY 2021 includes an an overall 16 percent increase in E/M codes fo

AACE 2021 Election Results

Congratulations to the newly elected Officers and Board members.

Now Available Online: Updated Bariatric Surgery Guidelines for 2019

AACE has released updated guidelines for the perioperative nutrition, metabolic and nonsurgical support of patients undergoing bariatric procedures.

Brief Report of Telemedicine Experience: Before and After the Crisis

AACE members Gauri Behari, MD, Karyne Vinales, MD, and Ricardo Correa MD, Es.D, share their experience with telemedicine tools both before and after the COVID-19 health crisis.

2019/2020 FACE Application Period is Closed

The FACE application period is from Monday, August 12, 2019, 8:00 am ET to Friday, November 01, 2019, 5:00 pm, ET. FACE Applications for 2020 will only be accepted through an online process.

Medullary Thyroid Carcinoma (MTC) Registry Consortium

The Medullary Thyroid Carcinoma (MTC) Registry Consortium* is partnering with the American Thyroi

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol

Ray KK, Bays HE, Catapano AL, et al.

AACE 2019 ELECTIONS - Preliminary Slate ELECT

A preliminary slate of candidates for the election of Officer positions for a one-year (1) term,

Mendelian Randomization Study of ACLY and Cardiovascular Disease

Ference BA, Ray KK, Catapano

Safety of Red Yeast Rice Supplementation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Fogacci F, Banach M, Mikhailidis DP et al.

Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials

Shin J, Chung JW, Jang HS et al.

New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease

Treatment of hypercholesterolemia with statins results in significant reductions in cardiovascular risk; however, individuals with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, but persistent high triglycerides (TG), remain at increased risk.

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Bhatt DL, Steg G, Miller M, et al.